Healthcare ❯ Drug Development

Clinical Trials

Regulatory Approval Patient Outcomes Phase II Trials Eli Lilly Market Competition Obesity Treatments Metabolic Diseases RNA Therapeutics Lung Cancer Treatment FDA Approval Efruxifermin AGAMREE Obesity Treatment GLP-1 Drugs FDA Regulations Patient Safety Efficacy Studies Treatment Options

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

The purchase underscores a push into MASH care under new leadership by betting on efruxifermin’s late-stage potential.

Blog Terms of Service Privacy Policy Help Partners About Us

Copyright © 2025 Mina Labs Inc.